Kymera Therapeutics (KYMR) Corporate presentation summary

Strategic vision and market opportunity

• Focus on developing first-in-class oral degrader medicines for immunological diseases, targeting historically undrugged pathways with biologics-like efficacy and convenience.

• Immunology remains a large, underserved market with over 160 million diagnosed patients and less than 3% receiving advanced systemic therapies, representing over $100B in annual sales.

• Oral degraders aim to overcome limitations of injectable biologics, such as inconvenience, immunogenicity, and high manufacturing costs, with over 90% of patients preferring oral options.

Pipeline highlights and clinical programs

• KT-621, an oral STAT6 degrader, demonstrated dupilumab-like efficacy in preclinical and early clinical studies, with robust biomarker and clinical endpoint improvements in atopic dermatitis (AD), asthma, and allergic rhinitis.

• KT-621 Phase 1b AD study showed deep STAT6 degradation, significant reductions in Type 2 biomarkers, and meaningful improvements in clinical and patient-reported outcomes, with a favorable safety profile.

• Ongoing Phase 2b trials for KT-621 in AD (BROADEN2) and asthma (BREADTH) are expected to report data by mid-2027 and late-2027, respectively.

• KT-579, a first-in-class oral IRF5 degrader, is in Phase 1 trials and targets broad autoimmune indications such as SLE, RA, and IBD, with preclinical data showing superior efficacy to approved drugs.

• KT-485, an oral IRAK4 degrader partnered with Sanofi, and a CDK2 molecular glue degrader partnered with Gilead, expand the pipeline into additional immunology and oncology indications.

Clinical and preclinical data insights

• KT-621 achieved rapid, robust reductions in EASI, SCORAD, itch, and quality of life measures, with results in line with or exceeding published dupilumab data at week 4.

• KT-621 demonstrated deep and sustained STAT6 degradation in blood and skin, with consistent biomarker and clinical improvements across all patient subgroups, including those with prior biologic exposure.

• KT-579 showed potent, selective IRF5 degradation, broad cytokine inhibition, and superior activity in lupus and RA mouse models compared to standard of care and other advanced therapies.

• KT-579 was well tolerated in non-human primate and rodent studies, with no adverse findings at doses achieving high levels of IRF5 degradation.